1. PF-00299804 in Treating Patients With Stage IIIB or Stage IV Non-Small Cell Lung Cancer That Has Not Responded to Standard Therapy for Advanced or Metastatic Cancer
ClinicalTrials.gov Identifier: NCT01000025
This randomized phase III trial is studying PF-00299804 to see how well it works compared with a placebo in treating patients with stage IIIB or stage IV non-small cell lung cancer that has not responded to standard therapy for advanced or metastatic cancer.
AB
Cross Cancer Institute, Edmonton
BC
BC Cancer Agency - Abbotsford Centre
BCCA - Fraser Valley Cancer Centre, Surrey
BCCA – Vancouver Cancer Centre
NB
Atlantic Health Sciences Corporation, Saint John
NS
QE2 Health Sciences Center, Halifax
NFLD
HR Bliss Cancer Center, St. John’s, NFLD
ON
Juravinski Cancer Centre, Hamilton
Cancer Centre of Southeastern Ontario, Kingston
London Regional Cancer Program, London
Lakeridge Health, Oshawa
Ottawa Health Research Institute, Ottawa
Algoma District Cancer Program, Sault Ste Marie
Niagara Health System, St. Catherine’s
Princess Margaret Hospital, Toronto
Windsor Regional Cancer Centre, Windsor
Regional Cancer program, Sudbury
QC
CHUM - Hopital Notre-Dame, Montreal
McGill University, Montreal
SK
Allan Blair Cancer Center, Regina
Saskatoon Cancer center, Saskatoon
2. ARQ 197 Plus Erlotinib Versus Placebo Plus Erlotinib for the Treatment of Non-squamous, Non-small-cell Lung Cancer
ClinicalTrials.gov Identifier: NCT01244191
This study is to determine if the combination regimen of ARQ 197 with erlotinib will improve overall survival relative to erlotinib alone in subjects with locally advanced or metastatic non-squamous, non-small cell lung cancer who have received 1 or 2 prior systemic anti-cancer therapies.
BC
Victoria
AB
Edmonton
MB
Winnipeg
QC
Montreal
Sainte-Foy
ON
Thunder Bay
Princess Margaret Hospital
London
3. Safety and Efficacy of BKM120 in Patients With Metastatic Non-small Cell Lung Cancer
ClinicalTrials.gov Identifier: NCT01297491
Purpose: The purpose of this two-stage phase II study is to assess the efficacy of BKM120, as measured by determining the progression free survival (PFS), in patients with pretreated metastatic Non-small Cell Lung Cancer (NSCLC) that exhibits PI3K pathway activation. BKM120 will be investigated in two groups of NSCLC patients according to the histology of the cancer: squamous and non-squamous
BC
BCCA, Vancouver
ON
Princess Margaret Hospital, Toronto
QC
Jewish general Hospital, Montreal
4. A Study of AUY922 in Non-small-cell Lung Cancer Patients Who Have Received Previous Two Lines of Chemotherapy
ClinicalTrials.gov Identifier: NCT01124864
Purpose: This study will assess the efficacy of AUY922, when administered weekly at 70 mg/m2, in adult patients with advanced NSCLC, who have received at least two prior lines of chemotherapy. Patients will be retrospectively, and prospectively, stratified based on their molecular tumor etiology. The following strata will be assigned: Patients with EGFR activating mutations, Patients with Kras activating mutations and patients that are both EGFR and Kras wild type.
AB
Cross Cancer Institute, Edmonton
QC
Jewish General Hospital, Montreal